Evidence map›Paper›PMID 37415974›Full record

ArticleFrontiers in immunology2023

MK2 drives progression of pancreas and colon cancers by suppressing CD8

Damian Jacenik, Eric J Lebish, Ellen J Beswick

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Damian JacenikDepartment of Cytobiochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Lodz, Poland.
Eric J LebishDivision of Gastroenterology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, United States.
Ellen J BeswickDivision of Gastroenterology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, United States.
University of Utah · USUniversity of Łódź · PL

Funding

G-CSF inhibition as a colorectal cancer therapyR01CA207051 · NCI · UNIVERSITY OF UTAH · PI BESWICK, ELLEN J. · 2016 to 2021
$1.7M
NCI NIH HHS R01 CA207051
6 · The paper itself

Abstract

Background: Immune cell composition is a critical and dynamic component of the tumor microenvironment, which has an impact on immunosuppression and progression of cancer. T cells, especially CD8 Methods: To explore the therapeutic potential of MK2 in the immune response mediated by CD8 Results: Here, we show that CD8 Conclusion: Overall, we documented that MK2 drives the progression of gastrointestinal cancers and prevents immune response generated by CD8

Indexed as

Antineoplastic AgentsColonic NeoplasmsAnimalsCD8-Positive T-LymphocytesImmunotherapyIntracellular Signaling Peptides and ProteinsMAP-Kinase-Activated Kinase 2MicePancreasProtein Serine-Threonine KinasesTumor MicroenvironmentAntineoplastic AgentsIntracellular Signaling Peptides and ProteinsMAP-Kinase-Activated Kinase 2Protein Serine-Threonine KinasesCD8+ T cellcolon cancercytotoxic T cellMAPKAPK2mitogen-activated protein kinase-activated protein kinase 2MK2pancreas cancertumorigenesis

Identifiers

PMID37415974
PMCPMC10321668
OpenAlexW4381662056

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.